Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (161-170 of 386) with videos related to

Pageof 39
Sort By:
BMJ Open|August 21, 2023
Implementation of the HepC<i>link</i> test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysisJuliana Reyes-Urueña, Francisco Costell-González, Laia Egea-Cortés, et al.
Journal of Viral Hepatitis|May 18, 2021
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and CErika Duffell, Helena Cortez-Pinto, Marieta Simonova, et al.
Antiviral Research|July 20, 2011
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter studySi-Nafa Si-Ahmed, Pierre Pradat, Roeland Zoutendijk, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 30, 2014
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b studyStefan Zeuzem, Jean-François Dufour, Maria Buti, et al.
Journal of Medical Virology|June 2, 2004
The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatmentPierre Pradat, Marianne Maynard, Maria Buti, et al.
Communications Medicine|May 12, 2023
Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in SpainJeffrey V Lazarus, Marcela Villota-Rivas, Pablo Ryan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 11, 2018
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis BDarren Wong, Margaret Littlejohn, Rosalind Edwards, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profilesLindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.
Scientific Reports|May 20, 2026
Cost-effectiveness of community interventions to promote awareness, testing and treatment of hepatitis B and C in migrant populations in CataloniaElisa Martró, Raquel Domínguez-Hernández, Venus Forero, et al.
Intervirology|September 25, 2008
Genotyping of hepatitis B virus--genotypes a to g by multiplex polymerase chain reactionWen-Chun Liu, Magnus Lindh, Maria Buti, et al.
Pageof 39

Showing results (161-170 of 386) with videos related to

Sort By:
Pageof 39
BMJ Open|August 21, 2023
Implementation of the HepC<i>link</i> test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: budget impact analysisJuliana Reyes-Urueña, Francisco Costell-González, Laia Egea-Cortés, et al.
Journal of Viral Hepatitis|May 18, 2021
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and CErika Duffell, Helena Cortez-Pinto, Marieta Simonova, et al.
Antiviral Research|July 20, 2011
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter studySi-Nafa Si-Ahmed, Pierre Pradat, Roeland Zoutendijk, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 30, 2014
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b studyStefan Zeuzem, Jean-François Dufour, Maria Buti, et al.
Journal of Medical Virology|June 2, 2004
The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatmentPierre Pradat, Marianne Maynard, Maria Buti, et al.
Communications Medicine|May 12, 2023
Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in SpainJeffrey V Lazarus, Marcela Villota-Rivas, Pablo Ryan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 11, 2018
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis BDarren Wong, Margaret Littlejohn, Rosalind Edwards, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profilesLindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.
Scientific Reports|May 20, 2026
Cost-effectiveness of community interventions to promote awareness, testing and treatment of hepatitis B and C in migrant populations in CataloniaElisa Martró, Raquel Domínguez-Hernández, Venus Forero, et al.
Intervirology|September 25, 2008
Genotyping of hepatitis B virus--genotypes a to g by multiplex polymerase chain reactionWen-Chun Liu, Magnus Lindh, Maria Buti, et al.
Pageof 39